CRISPR THERAPEUTICS
LIVE

Serial Number

98164705

Owner

CRISPR Therapeutics AG

Attorney

Tiffany D. Gehrke

First Use Date

Jul 22, 2019

Filing Date

Sep 5, 2023

Add to watchlist:

No watchlists yet
View on USPTO

CRISPR THERAPEUTICS Trademark

Serial Number: 98164705

CRISPR THERAPEUTICS is a trademark filed by CRISPR Therapeutics AG on September 5, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

CRISPR Therapeutics AG (50 trademarks)

ZUG V8 6300 , CH

Entity Type: 99

Trademark Details

Filing Date

September 5, 2023

Registration Date

Not Registered

First Use Anywhere

July 22, 2019

First Use in Commerce

July 22, 2019

Published for Opposition

January 7, 2025

Goods & Services

Education services, namely, providing online non-downloadable articles and newsletters in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy

Cells for medical or clinical use; pharmaceutical and biopharmaceutical agents for the treatment of cancer, infectious disease, autoimmune disorders, transplant rejections and inflammatory disease; pharmaceutical and biopharmaceutical preparations and substances for the treatment of cancer, infectious disease, autoimmune disorders, transplant rejections and inflammatory disease; pharmaceutical products and preparations, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of genetic diseases and disorders

Scientific research and development, namely, gene editing for researching and developing human cells and pharmaceuticals; research and development of therapeutics pharmaceuticals using gene editing; pharmaceutical, medical, scientific, and biopharmaceutical research and development, namely, providing medical and scientific research and development in the fields of pharmaceuticals and biopharmaceuticals; medical research laboratory services; scientific laboratory services; custom cell-line engineering services for scientific research purposes; medical and scientific research in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy; providing medical research and scientific research information in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy; scientific research and development services relating to targeting genetic therapies to individuals

Filing History

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 1, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 10, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 7, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 7, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 7, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 10, 2024 GNRN
NON-FINAL ACTION E-MAILED
May 10, 2024 GNRT
NON-FINAL ACTION WRITTEN
May 10, 2024 CNRT
ASSIGNED TO EXAMINER
May 1, 2024 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Sep 29, 2023 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 28, 2023 NWOS
NEW APPLICATION ENTERED
Sep 8, 2023 NWAP